(Q35640625)

English

Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease

scientific article published on December 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 August 2017

Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease (English)

1 reference

Europe PubMed Central

9 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Cancer and Leukemia Group B

5

object named as

Cancer and Leukemia Group B

1 reference

Europe PubMed Central

9 August 2017

author name string

James A Eastham

1

1 reference

Europe PubMed Central

9 August 2017

William K Kelly

2

1 reference

Europe PubMed Central

9 August 2017

Gary D Grossfeld

3

1 reference

Europe PubMed Central

9 August 2017

Eric J Small

4

1 reference

Europe PubMed Central

9 August 2017

language of work or name

0 references

publication date

1 December 2003

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

62 Suppl 1

1 reference

Europe PubMed Central

9 August 2017

55-62

1 reference

Europe PubMed Central

9 August 2017

Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

International Validation of a Preoperative Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Radical prostatectomy nomograms in black American men: accuracy and applicability

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Postoperative Nomogram for 12-Year Sarcoma-Specific Death

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Prediction of progression: nomograms of clinical utility

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Tr

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Growth and cell survival following treatment with estramustine nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145)

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Evidence for a non-estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Gene expression correlates of clinical prostate cancer behavior

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2003.09.052

7 January 2021

Identifiers

10.1016/J.UROLOGY.2003.09.052

1 reference

Europe PubMed Central

9 August 2017

1 reference

Europe PubMed Central

9 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35640625&oldid=1582231911"